Pharmaceutical group · United States
KING
A group of 7 companies with 30 medicines in 2 countries.
Group structure
7 companies in 3 countries
Loading your page…
Loading your page…
Pharmaceutical group · United States
A group of 7 companies with 30 medicines in 2 countries.
7 companies in 3 countries
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine of every company in the group, current ones first.
1–25 of 30
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ALTACE1.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 5MG **Federal Register · Tablet | Ramipril | United States | Not marketed | 2007 |
| ALTACE1.25mg | 10mg | 2.5mg | 5mg · Capsule | Ramipril | United States | Not marketed | 1991 |
| APOGEN10mg base/ml | 40mg base/ml · Injectable | Gentamicin | United States | Not marketed | |
| AVINZA120mg | 30mg | 45mg | 60mg | 75mg | 90mg · Capsule, extended release | Morphine | United States | Not marketed | 2002 |
| BICILLIN C-R150,000 units/ml; 150,000 units/ml | 300,000 units/ml; 300,000 units/ml · Injectable | Benzathine benzylpenicillin, Penicillin procaine | United States | Marketed | 1953 |
| BICILLIN C-R 900/300900,000 units/2ml; 300,000 units/2ml · Injectable | Benzathine benzylpenicillin, Penicillin procaine | United States | Marketed | 1953 |
| BICILLIN L-A300,000 units/ml | 600,000 units/ml · Injectable | Benzathine benzylpenicillin | United States | Marketed | 1952 |
| CORZIDE5MG; 40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 5MG; 80MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Bendroflumethiazide, Nadolol | United States | Not marketed | 1983 |
| CROMOPTIC4% · Solution/drops | Cromolyn | United States | Not marketed | 1999 |
| CYTOMEL0.005mg base | 0.025mg base | 0.05mg base · Tablet | Liothyronine sodium | United States | Marketed | 1956 |
| HUMATIN250mg base · Capsule | Paromomycin | United States | Not marketed | 1969 |
| INTAL0.8mg/inh · Aerosol, metered | Cromolyn | United States | Not marketed | 1985 |
| INTAL10MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Solution | Cromolyn | United States | Not marketed | 1982 |
| KLEBCIL1gm base/3ml | 500mg base/2ml | 75mg base/2ml · Injectable | Kanamycin | United States | Not marketed | |
| LEVOXYL0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | 0 · Tablet | Levothyroxine | United States | Marketed | 2001 |
| LORABID100mg/5ml | 200mg/5ml · For suspension | Loracarbef | United States | Not marketed | 1991 |
| LORABID200mg | 400mg · Capsule | Loracarbef | United States | Not marketed | 1991 |
| MAXOLON10mg base · Tablet | Metoclopramide | United States | Not marketed | |
| PROCANBID1gm | 500mg · Tablet, extended release | Procainamide | United States | Not marketed | 1996 |
| SILVADENE1% · Cream | Silver sulfadiazine | United States | Marketed | 1973 |
| SKELAXIN400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 800MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Metaxalone | United States | Not marketed | 1962 |
| SYNERCID500mg · Injectable | Quinupristin, Dalfopristin | United States | Marketed | 1999 |
| SYNERCID350mg/vial; 150mg/vial | 420mg/vial; 180mg/vial · Injectable | Dalfopristin, Quinupristin | United States | Not marketed | 1999 |
| TAPAZOLE10MG | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 5MG | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet | Thiamazole | United States | Not marketed | 1950 |
| TIGAN300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Capsule | Trimethobenzamide | United States | Not marketed | 1974 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 27 | 27 | 0 | CompaniesAll medicines |
| Canada | 3 | 0 | 3 | CompaniesAll medicines |
Also in the registers of Brazil, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; October 2026 register, published 7 October 2026; https://assets.publishing.service.gov.uk/media/6ac660fdec9d3aba1e0139d9/MS_Register_-_October_2026.csv; acquired 2026-10-13T22:59:02.704630+00:00; CSV-to-role/site projection is an adaptation under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; Crown copyright MHRA factual register
Report an error or request removalCorrections from the company itself are welcome.
Well-known pharmaceutical groups, each with all its companies.
Ranked by their number of medicines.